General Information

Government Type

State Agency

Entity

Department of Health and Human Services (DHHS)

Public Body

Drug Utilization Review Board

Notice Information

Add Notice to Calendar

Notice Title

State Medicaid DUR Committee Meeting

Notice Tags

Medicaid, Pharmacies

Notice Type(s)

Meeting

Event Start Date & Time

August 14, 2014 07:00 AM

Event End Date & Time

August 14, 2014 08:00 AM

Event Deadline Date & Time

08/07/14 06:00 PM

Description/Agenda

A public meeting and hearing of the Utah Department of Health State Medicaid Drug Utilization Review Board Thursday August 14th, 2014 Public meeting 7:00 a.m. to 8:00 a.m. Board Evaluation of Prior Authorization Requests 8:00 a.m. to 8:30 a.m. Cannon Health Building - Room 125 Agenda 1. Welcome………………………………………….………………..Tony Dalpiaz, Pharm.D., Board Chair 2. Housekeeping a. Housekeeping………………………….……………………………………….....Lisa Hunt, R.Ph. b. P&T Committee Report…………………………………………………………..Lisa Hunt, R.Ph. c. Approval of July Public Meeting Minutes.……………….Tony Dalpiaz, Pharm.D., Board Chair 3. New Hepatitis C Prior Authorization Criteria Update……………………………….Lisa Hunt, R.Ph. a. Public Comment b. Board Discussion/Questions c. Board Action 4. Proton Pump Inhibitors……………………………………Joanita Lake, B.Pharm, MSc EBHC (Oxon) a. Public Comment b. Board Discussion/Questions c. Board Action 5. Stimulants for Children Criteria Review…………………………………………… Lisa Hunt, R.Ph. a. Public Comment b. Board Discussion/Questions c. Board Action 6. Clonidine IR/ER tablets…………………...…………………………………………… Lisa Hunt, R.Ph. a. Public Comment: b. Board Discussion/Questions c. Board Action 7. Vote to close the meeting…............................................................Tony Dalpiaz, Pharm.D., Board Chair Board Meeting Agendas: Visitors may address the Board as time permits. To be added to the agenda, at least 7 days advance notice must be given. Please contact Robyn Seely, Pharm.D. at rmseely@utah.gov (preferred) or 801-538-6079. DUR Board Meeting Agendas are posted at least 14 days in advance, at http://www.utah.gov/pmn/index.html, in the Salt Lake Tribune, in the Deseret News and at the meeting location (Department of Health Cannon Building). Upcoming meetings for the next 6 months will be held in the Cannon Health Building, beginning at 7:00 a.m., 06/12/2014, 07/10/2014, 08/14/2014, 09/11/2014, 10/09/2014, and 11/13/2014. This is a proposed agenda. The actual meeting time may not allow for discussion of all proposed items. Agenda items not discussed in the meeting may be addressed during the next regularly scheduled meeting or during a future Board meeting. Business carried forward may be discussed at the next scheduled meeting(s). All data presented at DUR Board meetings reference gross paid claims from Utah Medicaid’s data warehouse. Final year-end dollar and unit amounts may be different due to ledger adjustment. The Purpose of the Drug Utilization Review Board: Utah Medicaid’s Pharmacy Department manages both a Drug Utilization Review (DUR) Board and a Pharmacy and Therapeutics (P&T) Committee. Provisions for the DUR Board are found in the Utah Administrative Code, Rule R414-60A. The P&T Committee is a sub-committee of the DUR Board and is provided for in the Utah Administrative Code, Rule R414-60B. The DUR Board’s goal is to ensure appropriate, medically necessary use of medications while preventing fraud, waste and abuse. To accomplish this, the DUR Board may recommend clinical prior authorization criteria for a medication. The P&T Committee’s goals are to establish the safety and efficacy of therapeutic classes of medications for possible inclusion on Utah Medicaid’s Preferred Drug List. Tentitive Future DUR Board Meeting Topics Month Topic Agents 9/11/2014 Topical Immunomodulator Agents Elidel (pimecrolimus) , Protopic (tacrolimus) Extended Release Agent clonidine HCL ER Antidiarrheal Agent Fulyzaq (crofelemer) 10/9/2014 Rheumatoid Arthritis (1) Conventional DMARDs: hydroxychloroquine, leflunomide, methotrexate, minocycline, and sulfasalazine (and combination therapy) Vaginal Products Osphena (ospemifene) 11/13/2014 Rheumatoid Arthritis Continued (2) Biologic Anti-TNF biologics: adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab (3) Biologic Non-TNF biologics: abatacept, anakinra, rituximab, tofacitinib and tocilizumab Anti-Influenza Oral Agents no PA reivew Tamiflu (oseltamivir), Relenza (zanamivir) 12/11/2014 Multiple Sclerosis Review #1 (1) self-injectable: Avonex, Betaseron, Copaxone, Extavia, Rebif Lidocaine Quantity Limits All similar and related products Sedative Hypnotic Hetlioz (tasimelteon) 1/8/2015 Multipl Sclerosis Review 2 (2) Infusion drugs: Novantrone, Tysabri (3) Oral drugs: Aubagio, Gilenya, Tecfidera Nine Month Review of no PA Sovaldi (sofosbuvir), Olysio (simeprevir) Possible Treatment of Hepititis C Expert Presentation Terry Box, M.D., Liver Transplant Program, University Hospital 2/12/2015 Nine Month Review Daliresp (roflumilast) 3/12/2015 Nine Month Review of no PA Juxtapid and Kynamro

Notice of Special Accommodations (ADA)

NOTICE OF SPECIAL ACCOMMODATION DURING PUBLIC MEETINGS In compliance with the Americans with Disabilities Act, individuals needing special accommodations (including auxiliary communicative aids and services) during this meeting should notify Trevor Smith at 801-538-7008 or Lisa Hunt at 801-538-6317.

Notice of Electronic or Telephone Participation

N/A

Meeting Information

Meeting Location

288 North 1460 West
Cannon Health Building, Room 125
Salt Lake City, 84116
Show in Apple Maps Show in Google Maps

Contact Name

Luis Moreno

Contact Email

lmoreno@utah.gov

Contact Phone

801-538-6155

Notice Posting Details

Notice Posted On

July 22, 2014 04:37 PM

Notice Last Edited On

July 29, 2014 08:56 AM

Deadline Date

August 7, 2014 06:00 PM

Subscribe by Email

Subscription options will send you alerts regarding future notices posted by this Body.